Αρχική World News Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or... World News Perioperative Durvalumab Plus FLOT Improves OS in Patients with Resectable Gastric or GEJ Adenocarcinoma Από Ogkologos - 15 Σεπτεμβρίου, 2026 102 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival analysis of the MATTERHORN study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ AI for early cancer detection: where are we now? Could virtual reality become a reality in cancer supportive care? EMA recommends granting a marketing authorisation for daraxonrasib MOST POPULAR Pink Van Makes the Rounds Throughout Rural New Zealand to Offer... 24 Φεβρουαρίου, 2021 A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials 7 Μαΐου, 2019 Patient Guide in Colorectal Cancer Now Available in Bulgarian 18 Φεβρουαρίου, 2026 Can Using Essential Oils Help Treat Cancer and Its Side Effects? 13 Ιουλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS 2021 ASCO Annual Meeting: Immunotherapy for Melanoma and Non-Small Cell Lung Cancer,... ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... Women Experience More Side Effects from Pelvic Radiation than Realized Pastor Opens Homeless Shelter And Moves In To Raise Money For...